Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxaliplatin
Drug ID BADD_D01633
Description Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. It is typically administered in combination with fluorouracil and leucovorin in a combination known as Folfox for the treatment of colorectal cancer. Compared to cisplatin the two amine groups are replaced by cyclohexyldiamine for improved antitumour activity. The chlorine ligands are replaced by the oxalato bidentate derived from oxalic acid in order to improve water solubility. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin®.
Indications and Usage Used in combination with infusional 5-FU/LV, is indicated for the treatment of advanced carcinoma of the colon or rectum and for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Marketing Status approved; investigational
ATC Code L01XA03
DrugBank ID DB00526
KEGG ID D01790
MeSH ID D000077150
PubChem ID 9887053
TTD Drug ID D0Y3ME
NDC Product Code 0703-3986; 13808-502; 0955-1733; 25021-233; 68083-171; 72603-101; 0955-1727; 57884-0017; 63592-0700; 50742-406; 55150-332; 67184-0501; 68083-170; 68083-176; 0955-1731; 72659-865; 43066-014; 68001-468; 71288-101; 82920-704; 16729-332; 45963-611; 67184-0502; 67184-0509; 0781-3317; 0781-9317; 67457-469; 0703-3985; 54875-0006; 67184-0510; 67457-442; 68083-314; 72266-126; 0781-3315; 50742-405; 71288-149; 72266-162; 0781-9315; 55150-331; 61703-363; 63323-750; 67184-0508; 72266-125; 72266-161; 72603-301; 79672-825; 0955-1725; 53104-7649; 67184-0007; 68554-0083; 60505-6132; 68083-177; 79672-826; 14778-0404; 49812-0075; 43066-018
UNII 04ZR38536J
Synonyms Oxaliplatin | Oxalato-(1,2-cyclohexanediamine)platinum II | Oxaliplatin, (SP-4-2-(1R-trans))-isomer | L-OHP Cpd | Platinum(II)-1,2-cyclohexanediamine Oxalate | 1,2-Diaminocyclohexane Platinum Oxalate | 1,2 Diaminocyclohexane Platinum Oxalate | 1,2-Diamminocyclohexane(trans-1)oxolatoplatinum(II) | Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) | Oxaliplatine | Eloxatine | Eloxatin | Oxaliplatin, (SP-4-3-(cis))-isomer | ACT 078 | ACT-078 | ACT078 | Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(II) | Oxaliplatin, (SP-4-2-(1S-trans))-isomer
Chemical Information
Molecular Formula C8H14N2O4Pt
CAS Registry Number 61825-94-3
SMILES C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Venous thrombosis limb24.01.02.0090.000112%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Lacrimal disorder06.08.02.005--Not Available
Myotonia17.05.02.013; 15.05.04.0130.000168%Not Available
Parkinson's disease17.01.05.0100.000280%Not Available
Red blood cell abnormality01.07.02.006--Not Available
Sensation of foreign body08.01.09.0020.001421%Not Available
Blood disorder01.05.01.0040.000246%Not Available
Autonomic neuropathy17.05.01.0090.000168%Not Available
Demyelinating polyneuropathy17.09.04.003; 10.04.10.0070.000112%Not Available
Disease progression08.01.03.0380.003492%
Disease recurrence08.01.03.0500.000392%Not Available
Neoplasm recurrence16.16.02.0040.000168%Not Available
Obstructive airways disorder22.03.01.0110.000504%Not Available
Cranial nerve paralysis17.04.01.002--Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000783%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Pigmentation disorder23.05.03.001--Not Available
Sensorimotor disorder17.05.03.0090.000280%Not Available
Venoocclusive disease24.03.02.0160.000224%Not Available
Metastasis16.22.01.0010.000280%Not Available
Muscle contracture15.03.05.0240.000582%Not Available
Dysaesthesia pharynx22.04.05.012; 17.02.06.0170.001567%
Effusion08.01.03.0520.000168%Not Available
Gastrointestinal inflammation07.08.03.0070.000112%Not Available
Device related infection11.01.08.018; 08.07.01.005--
Infusion site extravasation12.07.05.008; 08.02.05.0070.000246%
Infusion site paraesthesia17.02.06.026; 12.07.05.016; 08.02.05.0160.000168%Not Available
Bone marrow failure01.03.03.0050.001287%
Treatment failure08.06.01.0170.002239%Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 24 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene